{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:25:27Z","timestamp":1792783527931,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"This scientific research was funded by Shanghai Fifth People \u2019s Hospital, Fudan University","award":["No. 2023WYRH10"],"award-info":[{"award-number":["No. 2023WYRH10"]}],"id":[{"id":"https:\/\/ror.org\/013q1eq08","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"DOI":"10.1007\/s40262-026-01704-7","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T14:12:21Z","timestamp":1789999941000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PBPK Modeling of Coproporphyrin I Reveals Frailty-Associated Changes in Hepatic OATP1B1 Function in Chinese Adults"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4653-290X","authenticated-orcid":false,"given":"Longjie","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengfan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Like","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingfeng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8683-2603","authenticated-orcid":false,"given":"Xiaoqiang","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"issue":"11","key":"1704_CR1","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1172\/JCI107113","volume":"51","author":"N Kaplowitz","year":"1972","unstructured":"Kaplowitz N, Javitt N, Kappas A. Coproporphyrin I and III excretion in bile and urine. J Clin Invest. 1972;51(11):2895\u20139. https:\/\/doi.org\/10.1172\/JCI107113.","journal-title":"J Clin Investing"},{"issue":"5","key":"1704_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmd.2025.100073","volume":"53","author":"ER Hayden","year":"2025","unstructured":"Hayden ER, Xu V, Krotz L, Hockler JJ, Kaczynski BD, Sprowl JA. Coproporphyrin I as an in vitro fluorescent probe to measure OATP1B1 transport activity. Drug Metab Dispos. 2025;53(5):100073. https:\/\/doi.org\/10.1016\/j.dmd.2025.100073.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"1704_CR3","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/cpt.3649","volume":"118","author":"T Sumimoto","year":"2025","unstructured":"Sumimoto T, Tanaka R, Suzuki Y, et al. Impact of cancer cachexia progression on OATP1B1 transport activity: quantitative analysis using coproporphyrin-I as an endogenous biomarker. Clin Pharmacol Ther. 2025;118(1):128\u201337. https:\/\/doi.org\/10.1002\/cpt.3649.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"1704_CR4","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.clpt.2005.05.011","volume":"78","author":"RH Ho","year":"2005","unstructured":"Ho RH, Kim RB. Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther. 2005;78(3):260\u201377. https:\/\/doi.org\/10.1016\/j.clpt.2005.05.011.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"1704_CR5","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/j.1476-5381.2009.00430.x","volume":"158","author":"A Kalliokoski","year":"2009","unstructured":"Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009;158(3):693\u2013705. https:\/\/doi.org\/10.1111\/j.1476-5381.2009.00430.x.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"1704_CR6","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1124\/jpet.116.232066","volume":"357","author":"H Shen","year":"2016","unstructured":"Shen H, Dai J, Liu T, et al. Coproporphyrins I and III as functional markers of OATP1B activity: in vitro and in vivo evaluation in preclinical species. J Pharmacol Exp Ther. 2016;357(2):382\u201393. https:\/\/doi.org\/10.1124\/jpet.116.232066.","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"1704_CR7","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1124\/dmd.122.001012","volume":"51","author":"Y Lai","year":"2023","unstructured":"Lai Y. The role of coproporphyrins as endogenous biomarkers for organic anion transporting polypeptide 1B inhibition-progress from 2016 to 2023. Drug Metab Dispos. 2023;51(8):950\u201361. https:\/\/doi.org\/10.1124\/dmd.122.001012.","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"1704_CR8","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1002\/cpt.983","volume":"104","author":"S Barnett","year":"2018","unstructured":"Barnett S, Ogungbenro K, M\u00e9nochet K, et al. Gaining mechanistic insight into coproporphyrin I as endogenous biomarker for OATP1B-mediated drug-drug interactions using population pharmacokinetic modeling and simulation. Clin Pharmacol Ther. 2018;104(3):564\u201374. https:\/\/doi.org\/10.1002\/cpt.983.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"1704_CR9","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1124\/jpet.116.234914","volume":"358","author":"Y Lai","year":"2016","unstructured":"Lai Y, Mandlekar S, Shen H, et al. Coproporphyrins in plasma and urine can be appropriate clinical biomarkers to recapitulate drug-drug interactions mediated by organic anion transporting polypeptide inhibition. J Pharmacol Exp Ther. 2016;358(3):397\u2013404. https:\/\/doi.org\/10.1124\/jpet.116.234914.","journal-title":"J Pharmacol Exp Ther"},{"key":"1704_CR10","unstructured":"ICH harmonised guideline M12: drug interaction studies (International council for harmonization of technical requirements for pharmaceuticals for human use). 2024."},{"issue":"6","key":"1704_CR11","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00228-006-0123-1","volume":"62","author":"MK Pasanen","year":"2006","unstructured":"Pasanen MK, Backman JT, Neuvonen PJ, Niemi M. Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population. Eur J Clin Pharmacol. 2006;62(6):409\u201315. https:\/\/doi.org\/10.1007\/s00228-006-0123-1.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"1704_CR12","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.clpt.2005.06.013","volume":"78","author":"E Lee","year":"2005","unstructured":"Lee E, Ryan S, Birmingham B, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther. 2005;78(4):330\u201341. https:\/\/doi.org\/10.1016\/j.clpt.2005.06.013.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"1704_CR13","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1124\/jpet.302.2.804","volume":"302","author":"T Nozawa","year":"2002","unstructured":"Nozawa T, Nakajima M, Tamai I, et al. Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J Pharmacol Exp Ther. 2002;302(2):804\u201313. https:\/\/doi.org\/10.1124\/jpet.302.2.804.","journal-title":"J Pharmacol Exp Ther"},{"issue":"10","key":"1704_CR14","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1007\/s11095-021-03107-8","volume":"38","author":"W Kiander","year":"2021","unstructured":"Kiander W, Vellonen KS, Malinen MM, et al. The effect of single nucleotide variations in the transmembrane domain of OATP1B1 on in vitro functionality. Pharm Res. 2021;38(10):1663\u201375. https:\/\/doi.org\/10.1007\/s11095-021-03107-8.","journal-title":"Pharm Res"},{"issue":"8","key":"1704_CR15","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1124\/dmd.118.081125","volume":"46","author":"H Shen","year":"2018","unstructured":"Shen H, Christopher L, Lai Y, et al. Further studies to support the use of coproporphyrin I and III as novel clinical biomarkers for evaluating the potential for organic anion transporting polypeptide 1B1 and OATP1B3 inhibition. Drug Metab Dispos. 2018;46(8):1075\u201382. https:\/\/doi.org\/10.1124\/dmd.118.081125.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"1704_CR16","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.dmpk.2018.09.003","volume":"34","author":"D Mori","year":"2019","unstructured":"Mori D, Kashihara Y, Yoshikado T, et al. Effect of OATP1B1 genotypes on plasma concentrations of endogenous OATP1B1 substrates and drugs, and their association in healthy volunteers. Drug Metab Pharmacokinet. 2019;34(1):78\u201386. https:\/\/doi.org\/10.1016\/j.dmpk.2018.09.003.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"2","key":"1704_CR17","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/psp4.12582","volume":"10","author":"H Takita","year":"2021","unstructured":"Takita H, Barnett S, Zhang Y, et al. PBPK model of coproporphyrin I: evaluation of the impact of SLCO1B1 genotype, ethnicity, and sex on its inter-individual variability. CPT Pharmacomet Syst Pharmacol. 2021;10(2):137\u201347. https:\/\/doi.org\/10.1002\/psp4.12582.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"4","key":"1704_CR18","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s12291-013-0386-0","volume":"29","author":"DK Pasupula","year":"2014","unstructured":"Pasupula DK, Reddy PS. When is a South Indian really anemic? Indian J Clin Biochem. 2014;29(4):479\u201384. https:\/\/doi.org\/10.1007\/s12291-013-0386-0.","journal-title":"Indian J Clin Biochem"},{"key":"1704_CR19","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.leukres.2018.08.022","volume":"73","author":"Y Miyazaki","year":"2018","unstructured":"Miyazaki Y, Tuechler H, Sanz G, et al. Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: analysis from the International Working Group for Prognosis of MDS. Leuk Res. 2018;73:51\u20137. https:\/\/doi.org\/10.1016\/j.leukres.2018.08.022.","journal-title":"Leuk Res"},{"issue":"5","key":"1704_CR20","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1002\/cpt.2829","volume":"113","author":"J Lin","year":"2023","unstructured":"Lin J, Kimoto E, Yamazaki S, et al. Effect of hepatic impairment on OATP1B activity: quantitative pharmacokinetic analysis of endogenous biomarker and substrate drugs. Clin Pharmacol Ther. 2023;113(5):1058\u201369. https:\/\/doi.org\/10.1002\/cpt.2829.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"1704_CR21","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/cpt.2672","volume":"112","author":"H Takita","year":"2022","unstructured":"Takita H, Scotcher D, Chu X, Yee KL, Ogungbenro K, Galetin A. Coproporphyrin I as an endogenous biomarker to detect reduced OATP1B activity and shift in elimination route in chronic kidney disease. Clin Pharmacol Ther. 2022;112(3):615\u201326. https:\/\/doi.org\/10.1002\/cpt.2672.","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"1704_CR22","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1124\/dmd.124.001878","volume":"52","author":"Z Wang","year":"2024","unstructured":"Wang Z, Luk KHY, Cheong EJY, et al. Characterization and prediction of organic anion transporting polypeptide 1B activity in prostate cancer patients on abiraterone acetate using endogenous biomarker coproporphyrin I. Drug Metab Dispos. 2024;52(11):1356\u201362. https:\/\/doi.org\/10.1124\/dmd.124.001878.","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"1704_CR23","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1111\/cts.13272","volume":"15","author":"T Mochizuki","year":"2022","unstructured":"Mochizuki T, Aoki Y, Yoshikado T, et al. Physiologically-based pharmacokinetic model-based translation of OATP1B-mediated drug-drug interactions from coproporphyrin I to probe drugs. Clin Transl Sci. 2022;15(6):1519\u201331. https:\/\/doi.org\/10.1111\/cts.13272.","journal-title":"Clin Transl Sci"},{"issue":"10","key":"1704_CR24","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1002\/psp4.12849","volume":"11","author":"T Yoshikado","year":"2022","unstructured":"Yoshikado T, Aoki Y, Mochizuki T, et al. Cluster Gauss-Newton method analyses of PBPK model parameter combinations of coproporphyrin-I based on OATP1B-mediated rifampicin interaction studies. CPT Pharmacomet Syst Pharmacol. 2022;11(10):1341\u201357. https:\/\/doi.org\/10.1002\/psp4.12849.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1704_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3062","author":"K Ryota","year":"2023","unstructured":"Kikuchi R, Chothe PP, Chu X, et al.\u00a0Utilization of OATP1B biomarker coproporphyrin-i to guide drug\u2013drug interaction risk assessment: evaluation by the pharmaceutical industry. Clin Pharmacol Ther.\u00a02023;114(6):1170-1183. https:\/\/doi.org\/10.1002\/cpt.3062.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"1704_CR26","doi-asserted-by":"publisher","first-page":"M146","DOI":"10.1093\/gerona\/56.3.M146","volume":"56","author":"LP Fried","year":"2001","unstructured":"Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146\u201357. https:\/\/doi.org\/10.1093\/gerona\/56.3.M146.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"7","key":"1704_CR27","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s12603-012-0084-2","volume":"16","author":"JE Morley","year":"2012","unstructured":"Morley JE, Malmstrom TK, Miller DK. A simple frailty questionnaire (FRAIL) predicts outcomes in middle aged African Americans. J Nutr Health Aging. 2012;16(7):601\u20138. https:\/\/doi.org\/10.1007\/s12603-012-0084-2.","journal-title":"J Nutr Health Aging"},{"issue":"10","key":"1704_CR28","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/psp4.12134","volume":"5","author":"L Kuepfer","year":"2016","unstructured":"Kuepfer L, Niederalt C, Wendl T, et al. Applied concepts in PBPK modeling: how to build a PBPK\/PD model. CPT Pharmacomet Syst Pharmacol. 2016;5(10):516\u201331. https:\/\/doi.org\/10.1002\/psp4.12134.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"8","key":"1704_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2025.103866","volume":"114","author":"L Li","year":"2025","unstructured":"Li L, Zhu X, Xu W, et al. Physiologically-based pharmacokinetic modeling of rosuvastatin in Chinese: predicting the impact of SLCO1B1 and ABCG2 genetic variants and hepatic impairment on drug exposure. J Pharm Sci. 2025;114(8):103866. https:\/\/doi.org\/10.1016\/j.xphs.2025.103866.","journal-title":"J Pharm Sci"},{"issue":"10","key":"1704_CR30","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1007\/s11095-021-03109-6","volume":"38","author":"N Hanke","year":"2021","unstructured":"Hanke N, G\u00f3mez-Mantilla JD, Ishiguro N, Stopfer P, Nock V. Physiologically based pharmacokinetic modeling of rosuvastatin to predict transporter-mediated drug-drug interactions. Pharm Res. 2021;38(10):1645\u201361. https:\/\/doi.org\/10.1007\/s11095-021-03109-6.","journal-title":"Pharm Res"},{"issue":"1","key":"1704_CR31","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/cpt.1013","volume":"104","author":"M Shebley","year":"2018","unstructured":"Shebley M, Sandhu P, Emami Riedmaier A, et al. Physiologically based pharmacokinetic model qualification and reporting procedures for regulatory submissions: a consortium perspective. Clin Pharmacol Ther. 2018;104(1):88\u2013110. https:\/\/doi.org\/10.1002\/cpt.1013.","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"1704_CR32","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/psp4.12348","volume":"7","author":"T Yoshikado","year":"2018","unstructured":"Yoshikado T, Toshimoto K, Maeda K, et al. PBPK modeling of coproporphyrin I as an endogenous biomarker for drug interactions involving inhibition of hepatic OATP1B1 and OATP1B3. CPT Pharmacomet Syst Pharmacol. 2018;7(11):739\u201347. https:\/\/doi.org\/10.1002\/psp4.12348.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"5","key":"1704_CR33","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1002\/psp4.70008","volume":"14","author":"Y Ujihira","year":"2025","unstructured":"Ujihira Y, Tan SPF, Scotcher D, Galetin A. Genotype, ethnicity, and drug-drug interaction modeling as means of verifying transporter biomarker PBPK model: the coproporphyrin-I story. CPT Pharmacomet Syst Pharmacol. 2025;14(5):941\u201353. https:\/\/doi.org\/10.1002\/psp4.70008.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"5","key":"1704_CR34","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3109\/00498254.2015.1085111","volume":"46","author":"D Bednarczyk","year":"2016","unstructured":"Bednarczyk D, Boiselle C. Organic anion transporting polypeptide (OATP)-mediated transport of coproporphyrins I and III. Xenobiotica. 2016;46(5):457\u201366. https:\/\/doi.org\/10.3109\/00498254.2015.1085111.","journal-title":"Xenobiotica"},{"issue":"6","key":"1704_CR35","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1124\/dmd.116.074740","volume":"45","author":"RR Gilibili","year":"2017","unstructured":"Gilibili RR, Chatterjee S, Bagul P, et al. Coproporphyrin-I: a fluorescent, endogenous optimal probe substrate for ABCC2 (MRP2) suitable for vesicle-based MRP2 inhibition assay. Drug Metab Dispos. 2017;45(6):604\u201311. https:\/\/doi.org\/10.1124\/dmd.116.074740.","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"1704_CR36","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.trac.2008.09.002","volume":"27","author":"NC van de Merbel","year":"2008","unstructured":"van de Merbel NC. Quantitative determination of endogenous compounds in biological samples using chromatographic techniques. TrAC Trends Anal Chem. 2008;27(10):924\u201333. https:\/\/doi.org\/10.1016\/j.trac.2008.09.002.","journal-title":"TrAC Trends Anal Chem"},{"key":"1704_CR37","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jchromb.2017.12.008","volume":"1073","author":"E Njumbe Ediage","year":"2018","unstructured":"Njumbe Ediage E, Dillen L, Vroman A, et al. Development of an LC-MS method to quantify coproporphyrin I and III as endogenous biomarkers for drug transporter-mediated drug-drug interactions. J Chromatogr B Analyt Technol Biomed Life Sci. 2018;1073:80\u20139. https:\/\/doi.org\/10.1016\/j.jchromb.2017.12.008.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"1","key":"1704_CR38","doi-asserted-by":"publisher","first-page":"65","DOI":"10.4235\/agmr.23.0177","volume":"28","author":"I Vrettos","year":"2024","unstructured":"Vrettos I, Anagnostopoulos F, Voukelatou P, Kyvetos A, Theotoka D, Niakas D. Does old age comprise distinct subphases? Evidence from an analysis of the relationship between age and activities of daily living, comorbidities, and geriatric syndromes. Ann Geriatr Med Res. 2024;28(1):65\u201375. https:\/\/doi.org\/10.4235\/agmr.23.0177.","journal-title":"Ann Geriatr Med Res"},{"issue":"4","key":"1704_CR39","doi-asserted-by":"publisher","first-page":"92","DOI":"10.22540\/jfsf-05-092","volume":"5","author":"PK Sharma","year":"2020","unstructured":"Sharma PK, Reddy BM, Ganguly E. Frailty syndrome among oldest old individuals, aged \u226580 years: prevalence & correlates. J Frailty Sarcopenia Falls. 2020;5(4):92\u2013101. https:\/\/doi.org\/10.22540\/jfsf-05-092.","journal-title":"J Frailty Sarcopenia Falls."},{"issue":"5","key":"1704_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare10050895","volume":"10","author":"T-L To","year":"2022","unstructured":"To T-L, Doan T-N, Ho W-C, Liao W-C. Prevalence of frailty among community-dwelling older adults in Asian countries: a systematic review and meta-analysis. Healthcare (Basel). 2022;10(5):895.","journal-title":"Healthcare (Basel)"},{"key":"1704_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.exger.2023.112163","volume":"176","author":"E Tran Van Hoi","year":"2023","unstructured":"Tran Van Hoi E, De Glas NA, Portielje JEA, et al. Biomarkers of the ageing immune system and their association with frailty - a systematic review. Exp Gerontol. 2023;176:112163. https:\/\/doi.org\/10.1016\/j.exger.2023.112163.","journal-title":"Exp Gerontol"},{"issue":"8","key":"1704_CR42","doi-asserted-by":"publisher","first-page":"701","DOI":"10.14218\/jcth.2024.00017","volume":"12","author":"Y Guo","year":"2024","unstructured":"Guo Y, Zhang H, Zhao N, et al. STING-mediated IL-6 inhibits OATP1B1 expression via the TCF4 signaling pathway in cholestasis. J Clin Transl Hepatol. 2024;12(8):701\u201312. https:\/\/doi.org\/10.14218\/jcth.2024.00017.","journal-title":"J Clin Transl Hepatol"},{"issue":"1","key":"1704_CR43","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1124\/jpet.123.002019","volume":"391","author":"T Hao","year":"2024","unstructured":"Hao T, Tsang YP, Yin M, Mao Q, Unadkat JD. Dysregulation of human hepatic drug transporters by proinflammatory cytokines. J Pharmacol Exp Ther. 2024;391(1):82\u201390. https:\/\/doi.org\/10.1124\/jpet.123.002019.","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"1704_CR44","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s40264-023-01390-5","volume":"47","author":"EB Cohen","year":"2024","unstructured":"Cohen EB, Patwardhan M, Raheja R, et al. Drug-induced liver injury in the elderly: consensus statements and recommendations from the IQ-DILI initiative. Drug Saf. 2024;47(4):301\u201319. https:\/\/doi.org\/10.1007\/s40264-023-01390-5.","journal-title":"Drug Saf"},{"issue":"3","key":"1704_CR45","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/cpt.2643","volume":"112","author":"X Chu","year":"2022","unstructured":"Chu X, Prasad B, Neuhoff S, et al. Clinical implications of altered drug transporter abundance\/function and PBPK modeling in specific populations: an ITC perspective. Clin Pharmacol Ther. 2022;112(3):501\u201326. https:\/\/doi.org\/10.1002\/cpt.2643.","journal-title":"Clin Pharmacol Ther"},{"key":"1704_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.arr.2016.08.006","volume":"31","author":"P Soysal","year":"2016","unstructured":"Soysal P, Stubbs B, Lucato P, et al. Inflammation and frailty in the elderly: a systematic review and meta-analysis. Ageing Res Rev. 2016;31:1\u20138. https:\/\/doi.org\/10.1016\/j.arr.2016.08.006.","journal-title":"Ageing Res Rev"},{"issue":"3","key":"1704_CR47","doi-asserted-by":"publisher","first-page":"e180650","DOI":"10.1001\/jamanetworkopen.2018.0650","volume":"1","author":"K Wei","year":"2018","unstructured":"Wei K, Nyunt M-S-Z, Gao Q, Wee S-L, Yap K-B, Ng T-P. Association of frailty and malnutrition with long-term functional and mortality outcomes among community-dwelling older adults: results from the Singapore longitudinal aging study 1. JAMA Netw Open. 2018;1(3):e180650\u2013e180650. https:\/\/doi.org\/10.1001\/jamanetworkopen.2018.0650.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"1704_CR48","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1093\/ageing\/afab003","volume":"50","author":"SN Hilmer","year":"2021","unstructured":"Hilmer SN, Kirkpatrick CMJ. New horizons in the impact of frailty on pharmacokinetics: latest developments. Age Ageing. 2021;50(4):1054\u201363. https:\/\/doi.org\/10.1093\/ageing\/afab003.","journal-title":"Age Ageing"},{"issue":"3","key":"1704_CR49","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/cpt.3347","volume":"116","author":"JE Valerie Sia","year":"2024","unstructured":"Valerie Sia JE, Lai X, Mak WY, et al. Aging-related CYP3A functional changes in Chinese older patients: new findings from model-based assessment of amlodipine. Clin Pharmacol Ther. 2024;116(3):858\u201365. https:\/\/doi.org\/10.1002\/cpt.3347.","journal-title":"Clin Pharmacol Ther"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01704-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01704-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01704-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T14:12:25Z","timestamp":1789999945000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01704-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":49,"alternative-id":["1704"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01704-7","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"assertion":[{"value":"10 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declared no competing interests for this work.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data used to support the findings of this study are available from the corresponding author upon request.","order":2,"name":"Ethics","label":"Data Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was granted by the Ethics Committee of Shanghai Fifth People\u2019s Hospital, Fudan University (Approval No. [2024] Ethics Review No. 148, dated July 18, 2024).","order":3,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all participants prior to participation in the study.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Longjie Li and Mengfan Ye wrote the manuscript. Longjie Li, Mengfan Ye, Wenhang Xu, Xinyan Zhu, Like Xie, Haiping Xu, Qingfeng He, Xiao Zhu, Xiaoqiang Xiang, and Juan Xie conceived and designed the research. Longjie Li, Mengfan Ye, Wenhang Xu, Xinyan Zhu, Like Xie, Haiping Xu, Qingfeng He, and Xiao Zhu performed the research. Xiaoqiang Xiang and Juan Xie analyzed the data and supervised the study. All authors reviewed, revised, and approved the final manuscript.","order":5,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}